NeoImmuneTech Names Luke Oh President of BD

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, appointed Luke Oh, President. In his new role, Oh will spearhead NIT’s local team from its Rockville headquarters. His primary focus will be on accelerating the clinical development of NT-I7, NeoImmuneTech’s long-acting human IL-7, and strategizing the regulatory path for its potential inaugural approval for the treatment of Acute Radiation Syndrome (ARS).

Oh brings expertise in regulatory policies and drug development, with six years of regulatory experience at the U.S. FDA. His recent tenure at Samsung Bioepis as vice-president in charge of regulatory development was marked by the successful preparation and submission of seven biosimilar applications to regulatory agencies in the U.S., EU, UK, and Canada. Prior to this position, he worked as senior staff fellow at the U.S. FDA Division of Clinical Pharmacology III and Division of Inflammation and Immune Pharmacology. He has held various roles in research and development for leading organizations such as Mallinckrodt Pharmaceuticals, Human Genome Sciences, and Vertex Pharmaceuticals.

Se Hwan Yang, CEO of NeoImmuneTech, said, “We are delighted to welcome Dr. Oh to our team. His strong expertise and extensive network are invaluable assets that will propel our clinical development program and business activities. We wish him all success in his new role.”